NS 3623

Drug Profile

NS 3623

Latest Information Update: 23 Jan 2007

Price : $50

At a glance

  • Originator NeuroSearch
  • Class Phenylurea compounds; Tetrazoles
  • Mechanism of Action Ion channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Sickle cell anaemia

Most Recent Events

  • 27 Mar 2003 No development reported - Preclinical for Sickle cell anaemia in Denmark (unspecified route)
  • 18 May 2000 NS 3623 appears to be available for licensing (http://www.neurosearch.com)
  • 18 May 2000 Preclinical development for Sickle cell anaemia in Denmark (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top